Furthermore, 1G01, an NA-targeting mAb with an extended complementarity-determing region H3 loop (CDR3) obtained from an H3N2-infected individual, inhibited virtually all subtypes of influenza A and B both in vivo and in vitro, which makes it a strong candidate for universal anti-influenza targeted therapy (Hu et al., 2012). Here, XK is linked to influenza.